New report projects big growth in CNS biomarker market; Empire Genomics grabs biomarker for prostate cancer;

> A new report from BCC Research concludes that the CNS biomarker market, worth $2 billion in 2012, will grow to $5.1 billion in 2017. Factors driving that growth include an aging population alongside the growth of new public/private partnerships. Release

> Empire Genomics has grabbed a license for a biomarker that could be used to develop a new diagnostic test for neuroendocrine prostate cancer. Empire did the deal with Cornell. Report

> Medical researchers at the University of Alberta have pinpointed a genetic marker for sporadic breast cancer--one of a handful identified to date in Caucasians. Release

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

Drug-pricing watchdog ICER has partnered with medical data firm Aetion to help analyze the real-world performance of different treatments.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.